MedPath

Investiagtion of hormonal aspects of synaptic plasticity using a human surrogate model for central sensitizatio

Not Applicable
Conditions
Pain
Registration Number
DRKS00012301
Lead Sponsor
Klinik für Anästhesiologie, Operative Intensivmedizin und Schmerztherapie Universitätsklinikum Münster
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
37
Inclusion Criteria

voluntariness, age 18 - 40 years, regular menstrual cycle varying from 26 to 30 days

Exclusion Criteria

pregnancy, lactation, any medication (e. g. hormonal contraceptives, homones, anabolic steroids, analgesic, antidepressants), any pre-existing medical conditions (e.g. diabetes, migraine, multiple sclerosis, psychiatric disorder) or withdrawal of consent

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Baseline measurement: mechanical pain threshold (with PinPrick; MPT), mechanical pain sensibility (MPS), electrical pain sensibility (EPS), electrical detection threshold (EDT)<br>T0: immediatley after high frequency stimulation (HFS): MPT, MPS, EPS, EDT<br>T1: 1 hour after HFS: MPT, MPS, EPS, EDT<br>T3: three hours after HFS: MPT, MPS, EPS, EDT plus blood sampling<br>T27: 27 hours after HFS: MPT, MPS, EPS, EDT<br><br><br>Three measurements: follicular phase, late follicukar phase, luteal phase<br><br>High levles of progesterone (luteal phase) might amplify an induced primary and/ or secondary hyperalgesia. High levels of estrogen (late follicular phase) might decrease induced hyperalgesia.
Secondary Outcome Measures
NameTimeMethod
Measurement for area of hyperalgesia using a brush<br>T0;<br>T1;<br>T3; <br>T27.<br><br>Regression analysis might detect different gonodal hormones constellations that cause hyperalgesia.
© Copyright 2025. All Rights Reserved by MedPath